APPLIED DNA SCIENCES INC (APDN) Stock Fundamental Analysis

NASDAQ:APDN • US03815U6073

5.62 USD
+1.35 (+31.62%)
At close: Oct 6, 2025
6.18 USD
+0.56 (+9.96%)
After Hours: 10/6/2025, 9:22:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

APDN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. APDN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. APDN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year APDN has reported negative net income.
  • In the past year APDN has reported a negative cash flow from operations.
  • In the past 5 years APDN always reported negative net income.
  • In the past 5 years APDN always reported negative operating cash flow.
APDN Yearly Net Income VS EBIT VS OCF VS FCFAPDN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • The Return On Assets of APDN (-679.56%) is worse than 98.25% of its industry peers.
  • APDN has a Return On Equity of -929.59%. This is amonst the worse of the industry: APDN underperforms 94.74% of its industry peers.
Industry RankSector Rank
ROA -679.56%
ROE -929.59%
ROIC N/A
ROA(3y)-55.66%
ROA(5y)-76.19%
ROE(3y)-114.94%
ROE(5y)-140.25%
ROIC(3y)N/A
ROIC(5y)N/A
APDN Yearly ROA, ROE, ROICAPDN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K -1.5K

1.3 Margins

  • APDN has a Gross Margin of 39.57%. This is comparable to the rest of the industry: APDN outperforms 40.35% of its industry peers.
  • In the last couple of years the Gross Margin of APDN has declined.
  • APDN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 39.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.42%
GM growth 5Y-18.75%
APDN Yearly Profit, Operating, Gross MarginsAPDN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • APDN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for APDN has been increased compared to 1 year ago.
  • Compared to 5 years ago, APDN has more shares outstanding
  • APDN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
APDN Yearly Shares OutstandingAPDN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2K 4K 6K 8K 10K
APDN Yearly Total Debt VS Total AssetsAPDN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

  • APDN has an Altman-Z score of -54.74. This is a bad value and indicates that APDN is not financially healthy and even has some risk of bankruptcy.
  • APDN has a worse Altman-Z score (-54.74) than 94.74% of its industry peers.
  • APDN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -54.74
ROIC/WACCN/A
WACC10.45%
APDN Yearly LT Debt VS Equity VS FCFAPDN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M -15M

2.3 Liquidity

  • APDN has a Current Ratio of 2.76. This indicates that APDN is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 2.76, APDN perfoms like the industry average, outperforming 50.88% of the companies in the same industry.
  • A Quick Ratio of 2.60 indicates that APDN has no problem at all paying its short term obligations.
  • APDN has a Quick ratio (2.60) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.76
Quick Ratio 2.6
APDN Yearly Current Assets VS Current LiabilitesAPDN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • APDN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 89.59%, which is quite impressive.
  • Looking at the last year, APDN shows a decrease in Revenue. The Revenue has decreased by -2.96% in the last year.
  • APDN shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -8.63% yearly.
EPS 1Y (TTM)89.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-109.65%
Revenue 1Y (TTM)-2.96%
Revenue growth 3Y-27.56%
Revenue growth 5Y-8.63%
Sales Q2Q%-61.81%

3.2 Future

  • Based on estimates for the next years, APDN will show a very strong growth in Earnings Per Share. The EPS will grow by 40.85% on average per year.
  • The Revenue is expected to grow by 45.04% on average over the next years. This is a very strong growth
EPS Next Y92.97%
EPS Next 2Y40.85%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year50.26%
Revenue Next 2Y45.04%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
APDN Yearly Revenue VS EstimatesAPDN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M
APDN Yearly EPS VS EstimatesAPDN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -100K -200K -300K

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • APDN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year APDN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APDN Price Earnings VS Forward Price EarningsAPDN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APDN Per share dataAPDN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -200 -400 -600 -800

4.3 Compensation for Growth

  • APDN's earnings are expected to grow with 40.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.85%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • APDN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

APPLIED DNA SCIENCES INC

NASDAQ:APDN (10/6/2025, 9:22:01 PM)

After market: 6.18 +0.56 (+9.96%)

5.62

+1.35 (+31.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-14
Earnings (Next)12-15
Inst OwnersN/A
Inst Owner Change-5.86%
Ins OwnersN/A
Ins Owner Change0%
Market Cap7.25M
Revenue(TTM)3.30M
Net Income(TTM)-67.51M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-195.26%
Min EPS beat(2)-401.63%
Max EPS beat(2)11.11%
EPS beat(4)2
Avg EPS beat(4)-112.93%
Min EPS beat(4)-401.63%
Max EPS beat(4)11.11%
EPS beat(8)5
Avg EPS beat(8)-19.83%
EPS beat(12)8
Avg EPS beat(12)5.22%
EPS beat(16)10
Avg EPS beat(16)-1.91%
Revenue beat(2)0
Avg Revenue beat(2)-47.64%
Min Revenue beat(2)-76.62%
Max Revenue beat(2)-18.66%
Revenue beat(4)1
Avg Revenue beat(4)-23.38%
Min Revenue beat(4)-76.62%
Max Revenue beat(4)13.1%
Revenue beat(8)2
Avg Revenue beat(8)-20.61%
Revenue beat(12)5
Avg Revenue beat(12)-11.63%
Revenue beat(16)9
Avg Revenue beat(16)-3.58%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.2
P/FCF N/A
P/OCF N/A
P/B 1
P/tB 1.59
EV/EBITDA N/A
EPS(TTM)-924.25
EYN/A
EPS(NY)-84.15
Fwd EYN/A
FCF(TTM)-10.28
FCFYN/A
OCF(TTM)-9.75
OCFYN/A
SpS2.56
BVpS5.63
TBVpS3.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -679.56%
ROE -929.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 39.57%
FCFM N/A
ROA(3y)-55.66%
ROA(5y)-76.19%
ROE(3y)-114.94%
ROE(5y)-140.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.42%
GM growth 5Y-18.75%
F-Score4
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 205.74%
Cap/Sales 20.75%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.76
Quick Ratio 2.6
Altman-Z -54.74
F-Score4
WACC10.45%
ROIC/WACCN/A
Cap/Depr(3y)60.08%
Cap/Depr(5y)170.88%
Cap/Sales(3y)7.71%
Cap/Sales(5y)21.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)89.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-109.65%
EPS Next Y92.97%
EPS Next 2Y40.85%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-2.96%
Revenue growth 3Y-27.56%
Revenue growth 5Y-8.63%
Sales Q2Q%-61.81%
Revenue Next Year50.26%
Revenue Next 2Y45.04%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-86.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-85.04%
OCF growth 3YN/A
OCF growth 5YN/A

APPLIED DNA SCIENCES INC / APDN FAQ

Can you provide the ChartMill fundamental rating for APPLIED DNA SCIENCES INC?

ChartMill assigns a fundamental rating of 3 / 10 to APDN.


What is the valuation status of APPLIED DNA SCIENCES INC (APDN) stock?

ChartMill assigns a valuation rating of 1 / 10 to APPLIED DNA SCIENCES INC (APDN). This can be considered as Overvalued.


Can you provide the profitability details for APPLIED DNA SCIENCES INC?

APPLIED DNA SCIENCES INC (APDN) has a profitability rating of 0 / 10.


What is the expected EPS growth for APPLIED DNA SCIENCES INC (APDN) stock?

The Earnings per Share (EPS) of APPLIED DNA SCIENCES INC (APDN) is expected to grow by 92.97% in the next year.